Paper Details

  1. Home
  2. Paper Details

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Author: , AbdulkadyrovKudrat M, AndersonKenneth C, CakanaAndrew, DimopoulosMeletios A, DmoszynskaAnna, EsseltineDixie L, JiangBin, KhuagevaNuriet K, KropffMartin, LiuKevin, MateosMaria-Victoria, PalumboAntonio, PetrucciMaria T, RichardsonPaul G, SamoilovaOlga S, San MiguelJesús F, SchlagRudolf, SchotsRik, ShpilbergOfer, SpickaIvan, van de VeldeHelgi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3 study compared the effectiveness of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.
Paper Details　
Original Abstract of the Article :
The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible fo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa0801479

データ提供：米国国立医学図書館（NLM）

Treating Multiple Myeloma: A New Approach with Bortezomib

The realm of multiple myeloma treatment is vast and ever-evolving. Like navigating a desert, finding the right path to recovery can be tricky! This particular study, a phase 3 trial, explored a new route for treating multiple myeloma in patients who weren't suitable for high-dose therapy. The researchers compared the effectiveness of melphalan and prednisone, a standard treatment, with a new combination that included bortezomib. This study aimed to discover whether adding bortezomib to the standard regimen could improve outcomes for these patients.

Bortezomib Offers Promise for Multiple Myeloma Treatment

The study showed that adding bortezomib to the standard treatment of melphalan and prednisone improved the results for patients with multiple myeloma. The researchers observed a significant positive effect on the treatment outcomes, suggesting that bortezomib might be a valuable addition to the fight against this disease.

Navigating the Sands of Multiple Myeloma Treatment

This research highlights the importance of exploring different treatment options for multiple myeloma, especially for those who are not candidates for high-dose therapy. This study is like a well in the desert, offering a potential source of relief and hope for patients. Remember, the best approach for your own treatment will depend on your individual circumstances, so discussing these options with your doctor is essential.

Dr. Camel's Conclusion

The addition of bortezomib to the standard treatment of multiple myeloma shows promise for patients who are not suitable for high-dose therapy. This study is like a refreshing oasis in the arid landscape of multiple myeloma research, offering a new path towards better treatment outcomes.

Date :
  1. Date Completed 2008-09-03
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

18753647

DOI: Digital Object Identifier

10.1056/NEJMoa0801479

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.